BSECompany Update6d ago · 15 Oct 2026, 11:31 am

Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.

Zydus Lifesciences Ltd · 532321

✦ AI Summary▲ PositiveExpansion

Zydus Lifesciences Ltd has signed an agreement with the Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka, with a phased investment of over USD 20 million and commercial operations expected to commence in 2028.

Analysis Scores

Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Attachments (1)

📄

65b7aa93-4a49-4ef1-89bb-eafd443763ab.pdf

pdf

Download →
View document text
October 15, 2026 BSE Limited Code: 532321 P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a copy of press release dated October 15, 2026, titled “Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka”. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka Ahmedabad, India, 15 October, 2026 Dear Sir/Madam, We wish to inform you that Zydus Sunshine Lifesciences (Pvt) Ltd, the proposed joint venture between Zydus Lifesciences Limited (Zydus) and Sunshine Healthcare, part of Sunshine Holdings PLC, signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026 to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. Both companies had announced the formation of a Joint Venture on 26 June 2026. The project envisages a phased investment of over USD 20 million. The facility will be developed on a site of nearly four acres, with commercial operations expected to commence in 2028, subject to project timelines and relevant regulatory approvals. In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. The investment supports the Zydus’ international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka. Kindly take the above information on record.